Sign In | Join Free | My
Zhuhaishi Shuangbojie Technology Co., Ltd
Zhuhaishi Shuangbojie Technology Co., Ltd Semi-finished Steroids Oil, Peptides, SARMs and Steroids Raws Supplier
Home > Pharmaceutical Materials >

Pharmaceutical Inhibitors Apremilast / Otezla CAS 608141-41-9 to Treat Disease

Zhuhaishi Shuangbojie Technology Co., Ltd
Zhuhaishi Shuangbojie Technology Co., Ltd
City: Zhuhai
Province/State: Guangdong
Country/Region: China
Tel: 86-185-78209857
Contact Person:Mr luke

Pharmaceutical Inhibitors Apremilast / Otezla CAS 608141-41-9 to Treat Disease

Brand Name : Shuangbojie
Model Number :
Certification : Enterprise Standard
Place of Origin : China
MOQ : 10g
Price : Negotiation
Payment Terms : Western Union, MoneyGram, Bitocin, T/T
Supply Ability : 500kg/Month
Delivery Time : Within 24 hours
Packaging Details : Discreet Package
CAS : 608141-41-9
MF : C22H24N2O7S
MW : n/a
Apperance : Powder
EINECS : n/a
Packing : Discreet Packing
WhatsAPP : +8618578209860
Contact Now

Pharmaceutical Inhibitors Apremilast / Otezla CAS 608141-41-9 to Treat Disease

Product Name: Apremilast (CC-10004)
Synonyms: ApreMilast;(S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide;ApreMilast,CC-10004;AcetaMide, N-[2-[(1S)-1-(3-ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-;Appleton West;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide Apremilast (CC-10004;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)
CAS: 608141-41-9
MF: C22H24N2O7S

Apremilast Description

Apremilast (Otezla) was approved by the FDA on March 21, 2014 for the treatment of adult patients with active psoriatic arthritis. Apremilast is a member of a new class of oral small molecule inhibitors of the phosphosphodiesterase 4 (PDE4) enzyme. When PDE4 is inhibited in immune cells, it results in elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, which can regulate inflammatory mediators. The current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults.

Apremilast Uses

Treating active psoriatic arthritis. It is also used to treat moderate to severe plaque psoriasis in certain patients.

Apremilast Metabolism and Drug interaction

Oral administration of apremilast has an absolute biovailability of 73% with peak concentration at 2.5 hours (Tmax). The half-life of apremilast is 6-9 hours. Apremilast is metabolized by the both cytochrome (CYP) and non-CYP pathways. In vitro studies have demonstrated that apremilast metabolism is primarily mediated by the CYP3A4 pathway. Thus, concomitant use of apremilast with CYP450 enzyme inducers (such as rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended. There are no significant drug-drug interactions with oral contraceptives, ketoconazole, or methotrexate.

Apremilast safety information

1. Apremilast may cause depression. The risk may be greater in patients who have a history of depression or suicidal thoughts or actions. Families and caregivers must closely watch patients who take apremilast. It is important to keep in close contact with the patient's doctor. Tell the doctor right away if the patient has new, worsened, or sudden symptoms, such as depression; anxiety, restlessness, or irritability; panic attacks; or any changes in behavior. Contact the doctor right away if any signs of suicidal thoughts or actions occur.
2. Apremilast may cause weight loss. You will need to have regular weight checks while you are taking apremilast.

DNP / Sodium 2,4-dinitrophenate
Methylamine hydrochloride
gamma-Butyrolactone / GBL
Benzyl benzoate
Benzyl alcohol
Ethyl Oleate
4-Acetamidophenol / Paracetamol
Tranexamic acid / Amstat
Raloxifene hydrochloride
Synephrine hydrochloride
Lorcaserin hydrochloride hemihydrate
Triamcinolone acetonide acetate
Adrenosterone / 11-OXO
Pramipexole Hydrochloride
Apremilast (CC-10004) / Otezla

Product Tags:

pharmaceutical raw materials


pharmaceutical drugs

China Customized Inflatable Bumper Ball Game Bubble Adult Grass CE supplier

Pharmaceutical Inhibitors Apremilast / Otezla CAS 608141-41-9 to Treat Disease Images

Inquiry Cart 0
Send your message to this supplier
To: Zhuhaishi Shuangbojie Technology Co., Ltd
Characters Remaining: (0/3000)

Home| Products| Suppliers| Quality Suppliers| Site Map |About Us |Contact Us |Help |关于我们 |联系我们

Copyright © 2009 - 2018 All rights reserved.